[Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].
Zhonghua Xue Ye Xue Za Zhi
; 37(3): 221-6, 2016 Mar.
Article
em Zh
| MEDLINE
| ID: mdl-27033760
ABSTRACT
OBJECTIVE:
To investigate the morbidity, treatment outcomes and prognosis of 35 therapy-related hematological neoplasms patients.METHODS:
A total of 35 cases of therapy-related hematological neoplasms were examined genetically and immunologically using flow cytometry, karyotype analysis and FISH, and their clinical data were retrospective analyzed and literatures were reviewed.RESULTS:
Among 35 patients, there were 20 cases of therapy-related acute myeloid leukemia (t-AML), 4 cases of therapy-related acute lymphoblastic leukemia (t-ALL), 1 case of acute mixed leukemia, therapy-related non-hodgkin' s lymphoma (t-NHL) in 8 cases and myelodysplastic syndrome (t-MDS) in 2 cases. The median onset of t-HN was 29(16-90) months, the median OS of t-HN was 14(1-60) months, and 3 years of OS was 17.1%. Among therapy-related acute leukemia (t-AL) patients, 40% (10/25) patients had combined complex karyotype, 36% (9/25) patients with MLL gene rearrangement, 12% (3/25) patients with combined AML/ETO fusion gene, 1 case with NPM1 point mutation and 1 case with P16 gene deletion.CONCLUSIONS:
Therapy-related hematological neoplasms had a worse prognosis.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Segunda Neoplasia Primária
/
Neoplasias Hematológicas
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2016
Tipo de documento:
Article